ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2597

Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis

Paula Song1, Melody Chung 2, Shufeng Li 3, David Fiorentino 4 and Lorinda Chung 2, 1Department of Medicine, Santa Clara Valley Medical Center, Palo Alto, CA, 2Stanford University, Palo Alto, CA, 3Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA, 4Department of Dermatology, Stanford University School of Medicine, Redwood City, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Degos Disease, Degos lesions, Systemic sclerosis, vasculopathy and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Degos disease, also known as malignant atrophic papulosis (MAP), is a rare small-vessel vasculopathy that has characteristic cutaneous manifestations consisting of erythematous telangiectatic rims with porcelain-white atrophic centers with variable gastrointestinal vasculopathy that can be fatal (Figure 1). Studies suggest that endothelial dysfunction and immune dysregulation may play a role in subsequent intimal proliferation and occlusive vasculopathy in cutaneous Degos lesions. Lesions that mimic the cutaneous findings in Degos disease have been described in other rheumatic diseases, although their significance is unclear. We sought to evaluate the prevalence and clinical associations of Degos lesions in patients with systemic sclerosis (SSc).

Methods: This was a retrospective cohort study of 504 patients with SSc, who were seen at a tertiary referral center between 1998 and 2018. All patients fulfilled 2013 ACR/EULAR classification criteria for SSc. Demographics, autoantibodies, and cutaneous and internal organ manifestations of patients with and without Degos lesions were compared using chi-squared tests for categorical variables, accounting for missing data. Logistic regression analyses were performed to evaluate whether Degos lesions were predictive of any internal organ complications.

Results: Of 504 SSc patients, 21 (4.2%) had Degos lesions. In 19 (90.5%), Degos lesions were found on the hands, notably the fingers. Two patients had Degos lesions involving the lower extremities. Degos lesions were significantly associated with acro-osteolysis, calcinosis, and digital ischemic loss (Table 1). There was a trend towards statistically significant associations with diffuse SSc subtype and telangiectasias. We further assessed whether Degos lesions were predictive of any internal organ complications. We found a trend, both in univariate and multivariate logistic regression analyses, towards an association with GAVE (Table 2).

Conclusion: Degos lesions are present in 4.2% of our SSc cohort. Degos lesions are associated with other cutaneous manifestations of SSc including acro-osteolysis, calcinosis, and digital ischemia, supporting an underlying ischemic and vasculopathic etiology. Our findings suggest that Degos lesions may be associated with the presence of GAVE.

Figure 1. Right index finger of a patient with SSc showing two Degos lesions, which are characterized by erythematous telangiectatic rims with porcelain-white atrophic centers


Degos Table 1


Degos Table 2


Disclosure: P. Song, None; M. Chung, None; S. Li, None; D. Fiorentino, Janssen, 5, Pfizer, 2, 5, UCB Pharmaceuticals, 5; L. Chung, BMS, 6, 9, Boehrenger-Ingelheim, 5, Boehringer Ingelheim, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squib, 5, Eicos, 5, 6, 9, Eicos Steering Committee, 5, Mitsubishi Tanabe, 5, Reata, 5, 6, Reata DSMB, 5, Reatta, 5.

To cite this abstract in AMA style:

Song P, Chung M, Li S, Fiorentino D, Chung L. Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/prevalence-and-clinical-associations-of-degos-lesions-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-clinical-associations-of-degos-lesions-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology